Guide to Pharmacovigilance Technology & AI in Drug Safety

Pharmacovigilance (PV) – the science of monitoring, detecting, and preventing adverse drug reactions (ADRs) – has entered a new technological era. This report surveys the pharmacovigilance tech landscape in unprecedented depth. We review the historical evolution and current state of PV, the modern tools and methods in use (including safety databases, automation, AI/ML, real-world data, social listening, and mobile applications), and the regulatory and industry context. We examine key trends such as the adoption of artificial intelligence (AI) and machine learning (ML) for case processing and signal detection (^[1]) (^[2]), the integration of real-world data (RWD) via networks like FDA’s Sentinel (^[3]), the use of mobile apps and wearables to capture patient-reported outcomes (^[4]) (^[5]), and emerging standards (e.g. ISO IDMP) for data interoperability (^[6]). We present case studies illustrating these developments – from a pilot where an AI/Bayesian network accelerated causality assessment of ADRs (^[7]), to the global WHO VigiBase system holding over 40 million reports (^[8]). We also cover the latest regulatory developments, including the FDA's January 2025 draft guidance on AI in drug regulation, the joint FDA-EMA guiding principles on AI (January 2026), and the emergence of generative AI and large language models (LLMs) in PV workflows. The report discusses challenges (data quality, privacy, regulatory requirements) and looks ahead to future directions: predictive safety analytics, digital therapeutics, and further convergence of health informatics and PV. All claims are supported by extensive citations to scientific articles, industry reports, and official sources.

Pharmacovigilance (PV) is an essential part of drug safety, concerned with the identification, assessment, and prevention of adverse effects of pharmaceuticals. It traces back to the thalidomide tragedy of the 1960s, after which regulatory systems were established to collect safety reports. Even today, ADRs remain a major public health problem – in the US alone ADRs account for “at least 7,000 fatalities annually” (and tens of billions USD in costs) (^[9]). Globally, the World Health Organization’s (WHO’s) Uppsala Monitoring Centre curates VigiBase, the world’s largest database of post-market safety reports. As of early 2026, VigiBase contains over 40 million Individual Case Safety Reports (ICSRs) from more than 180 member states covering approximately 99% of the world's population (^[8]). A process to upgrade all historical VigiBase reports to the ICH E2B(R3) format is planned for 2026. These vast datasets underpin signal detection efforts but also pose data management challenges.

Traditionally, PV relied on spontaneous reporting (via forms like CIOMS/MedWatch in structured fields) and manual case review. Over time, PV has evolved to utilize computerized databases (e.g. FDA’s FAERS, EudraVigilance) and standardized data formats (such as the ICH E2B standard for electronic ICSRs) to facilitate global reporting. In parallel, adverse event signal detection has used methods like disproportionality analysis (proportional reporting ratios, Bayesian shrinkage, etc.) to flag unusual drug-event pairs.

Today, PV is undergoing a digital transformation. New technologies – such as robotic process automation (RPA), natural language processing (NLP), and AI/ML – promise to streamline PV workflows and extract insights from unstructured sources (medical literature, electronic health records, social media). Huge bodies of real-world data (claims, EHRs, device data) are now available to augment traditional safety data. Regulatory agencies are encouraging such innovations: for example, the FDA Sentinel system (established 2008) uses a common data model to run distributed analyses on healthcare data (^[3]), and the EU has mandated standardized medicine identification (ISO IDMP) to improve data interoperability (^[6]).

Nevertheless, challenges remain. Data heterogeneity, privacy concerns, the need for expert validation, and regulatory requirements constrain how modern tech can be deployed. A balanced assessment (industry and regulators) stresses that human oversight remains essential, even as automation increases (^[10]). This report aims to provide a comprehensive view of the current PV tech landscape and its trajectory.

The PV technology journey spans decades of regulatory developments and technological advances. Key milestones include:

• 1960s–1990s: Emergence of Spontaneous Reporting Systems. In the aftermath of early drug safety crises, regulators established spontaneous reporting forms (paper CIOMS, MedWatch, Yellow Card, etc.) and set up national PV centers (UK, FDA, EMA, etc.). Example: FDA’s MedWatch (started 1993) and the UK’s Yellow Card scheme generate structured ICSRs submitted by physicians and manufacturers.

• 2000s: Computerization and Data Standards. The turn of the century saw globalization of PV. The International Council for Harmonisation’s E2B(R2) standard (2001) defined electronic ICSR formats, enabling automated exchange of safety reports. Commercial PV databases (e.g. Oracle Argus, ArisGlobal ARISg) entered the market, digitizing case processing. Meanwhile, WHO launched VigiBase (Uppsala, 1968) and began VigiFlow, a web-based reporting system (2004). By mid-2000s, mandatory post-market surveillance and new regulatory frameworks (e.g. EU Directives, FDA Amendments Act 2007) increased case volumes.

• 2010s: Data Mining and International Collaboration. With millions of ICSRs, statistical signal detection became routine. The EU’s EudraVigilance (est. 2001) expanded dramatically, eventually requiring ISO/ICH E2B(R3) in 2022. The FDA established the Sentinel Network (2008) linking multiple data partners under a common model. Real-World Evidence (RWE) gained traction under initiatives like NEOMA, BEST (biologics initiative), and EMA’s DARWIN project for data analysis. Social media and web data began to be explored as supplementary sources (e.g. WEB-RADR project in 2014 launched a mobile reporting app).

• 2020s: AI, RWD, and Harmonization. The last few years have seen rapid interest in AI/ML and advanced analytics for PV. Pilot studies demonstrated the feasibility of AI-driven case processing (^[1]). Consortia (TransCelerate, PVNet) surveyed industry; by 2021 many companies planned or began using intelligent automation (RPA, NLP, machine learning) in PV (^[11]) (^[12]). Regulators are transitioning to newer standards: ICH updated the E2B(R3) Q&As and Implementation Guide in July 2025, merging the Q&As into the guide; the EU has mandated E2B(R3) since June 2022, and ISO IDMP compliance is expanding globally for product data (^[6]). Wearable sensors and telehealth tools are being piloted to provide continuous safety monitoring (^[13]) (^[5]).

• 2025–2026: Generative AI and Regulatory Maturation. The PV landscape has entered a new phase with the arrival of generative AI and large language models (LLMs) in production workflows. Vendors like ArisGlobal (NavaX GenAI), Oracle (Safety One Intake), and Veeva (Vault AI Agents) have deployed LLM-powered tools for automated case intake, MedDRA coding, and narrative generation – with reported efficiency gains of 65–90% in case processing. In January 2025, FDA issued draft guidance describing a risk-based credibility-assessment framework that may be used when an AI model produces information or data intended to support FDA regulatory decision-making about drug safety, effectiveness, or quality. The document is not for implementation, contains non-binding recommendations, and does not address AI used solely for operational efficiencies that do not affect patient safety, drug quality, or study-result reliability (^[14]). Looking ahead, PV is moving from largely retrospective reporting to more proactive, predictive surveillance powered by big data and intelligent algorithms (^[15]).

Safety Databases and Reporting Tools

Modern PV relies on specialized safety databases and case management platforms. These systems ingest and store ICSRs, support medical coding (e.g. MedDRA terms for symptoms, WHO-Drug codes), and enable regulatory reporting. Key examples include:

• Oracle Argus Safety (Oracle Corporation): Oracle documents Argus as a pharmacovigilance platform for adverse-event case processing and regulatory reporting. Its optional Safety One Intake service uses OCR and NLP to extract information from adverse-event source documents for review before case processing (^[16]).

• ArisGlobal LifeSphere Safety (ArisGlobal): A cloud-native PV suite with GenAI-driven case processing via its NavaX platform. On 3 June 2025, ArisGlobal said a sixth major pharmaceutical organization had selected NavaX; that customer’s implementation was planned for fall 2025. ArisGlobal stated that the customer expected up to 65% case-processing efficiency gains and 90% intake-data accuracy.

• Veeva Vault Safety (Veeva Systems): A cloud-first platform (launched 2018) designed for biotechs and CROs. Vault Safety offers a modern user interface and supports seamless global reporting, focusing on usability and integration with other Veeva products (^[17]). In April 2025, Veeva announced Vault AI Agents embedding LLMs into Vault applications for auto-summarizing, workflow recommendations, and auto-filling fields. Safety & Quality AI Agents (scheduled April 2026) will bring agentic AI capabilities to safety case processing and triage.

• Other Commercial Tools: Mid-tier options include Ennov PV-Works (hybrid cloud/on-prem, popular in small/medium companies), SafetyEasy (by AB Cube/EXTEDO, hybrid model), and Accelovance CLAIRE. Each provides core PV functions (case entry, MedDRA coding, narrative writing, electronic submissions) but varies in scale and technology approach (^[17]). Table 1 (below) compares selected platforms.

Table 1: Comparison of representative pharmacovigilance software systems and databases. (Source: industry reviews (^[21]) (^[17]).)

These platforms are continually evolving. Oracle's Safety One Intake uses AI to automate extraction from unstructured safety documents, reducing manual entry by up to 90%; on 3 June 2025, ArisGlobal reported that a sixth major pharmaceutical organization had selected NavaX, with implementation planned for fall 2025; and Veeva's Vault AI Agents (launching April 2026) will embed LLM-based agentic workflows directly into safety case processing. Industry surveys note that while “rule-based automations” (RPA, lookups) are already widely implemented, interest in cognitive tools (ML/NLP) is rising (^[12]) (^[11]). Notably, TransCelerate’s member companies report that as of 2021 every step in ICSR processing has at least some automation (even if still in pilot) (^[22]).

Data Standards and Interchange

To function smoothly, PV systems rely on data standards for report interchange and coding:

• MedDRA: The Medical Dictionary for Regulatory Activities provides standardized terms for adverse events and indications (latest release: MedDRA 29.0, March 2026, with 198 new Preferred Terms and 611 new Lowest Level Terms). All major PV systems incorporate MedDRA coding to unify free-text symptom narratives.

• WHO Drug Dictionary: Codes for active ingredients and medicinal products, often used with the WHO-Drug classification.

• ICH E2B(R3): The International Council for Harmonisation standard (latest version R3) specifies XML formats and data fields for electronic ICSRs. In July 2025, ICH updated the package by merging the Q&As into the Implementation Guide; ICH’s document history identifies these as updates made after Step 4. The EU has mandated E2B(R3) for EudraVigilance since June 2022, the FDA has issued guidance and validator tools for R3 readiness, and Japan (PMDA), China, and Canada are moving toward harmonization (^[23]). E2B(R3) allows richer data capture (e.g. unique identifiers, structured narratives). WHO's VigiBase plans to upgrade all historical reports to the R3 format in 2026.

• ISO IDMP (SPOR data): The ISO Identification of Medicinal Products standards (ISO 11615/11616) define controlled vocabularies for describing substances, products, organizations, and referential data. The EU requires IDMP-compliant submissions of product information (SPOR database) (^[6]), facilitating interoperability. EMA is releasing its Public PMS API at the end of Q1 2026, with enrichment compliance required for all medicines by end of 2026. Other regions (Japan, Canada) are also moving toward IDMP.

• Other Messaging Standards: Many PV systems support HL7 interfaces or FHIR APIs to exchange safety data with electronic health record (EHR) systems and regulatory portals. For example, systems may accept ICSRs in HL7 CDA format from hospital systems.

• Coding and Quality Checks: Incoming reports to databases are validated against minimum data criteria (e.g. patient ID, suspect drug, event) and standardized via vocabularies to ensure high data quality for downstream analysis (^[24]). Modern systems often include built-in coding suggestions (e.g. MedDRA synonyms) and duplicate detection algorithms.

Overall, these standards create an ecosystem in which safety data can flow internationally and across stakeholders. However, the complexity of merging different data sources (spontaneous reports, EHRs, literature) remains a technical challenge requiring harmonization efforts.

Traditional Signal Detection

Pharmacovigilance has long used disproportionality analyses on large safety databases to generate signals (drug-event associations that occur more often than expected). Methods such as the Proportional Reporting Ratio (PRR) or Empirical Bayes metrics scan millions of ICSRs to flag potential risks. These approaches, while well-established, have limitations (they require sufficient report volume and can produce false positives from confounding) (^[25]). Recent work has refined these methods – for example, guidelines (the READUS-PV guideline) improve transparency in reporting disproportionality results (^[26]).

AI/ML for Signal Detection

In the 2020s, PV has seen growing use of AI/ML for safety signal analytics beyond simple disproportionality.

• Machine Learning on RWD: AI models are being trained on structured real-world data (EHRs, claims) to detect safety signals. For example, scoping reviews find many studies using ML on claims/EHR to predict adverse drug events (^[27]). These models often focus on patient-level ADR risk prediction rather than population-wide signal detection (^[28]), suggesting an emerging trend toward personalized pharmacovigilance. Key algorithms include logistic regression, random forests, and deep learning. However, reviews note gaps: explainable AI (XAI) and causal modeling are not yet widely applied, and many models lack external validation (^[28]).

• Natural Language Processing (NLP): Unstructured data – patient narratives, social media, journal articles – are rich sources of ADR information. A systematic review found that NLP applied to user-generated content (tweets, forums, blogs) can successfully identify reported ADRs (^[29]). For example, NLP systems analyzing health forum posts were able to detect known side effects and even novel symptom clusters (^[30]). Roughly 88% of studies reported positive outcomes using NLP for ADR identification (^[29]). These findings indicate social media can complement traditional reporting by catching signals earlier or in populations underrepresented in official data (^[31]). However, challenges include dealing with noisy slang and ensuring representativeness.

• Bayesian and Probabilistic Models: Bayesian networks and other probabilistic models are gaining interest for safety assessment. A notable practical case is an “expert-defined Bayesian network” for causality assessment implemented at a pharmacovigilance center. According to a 2025 report, this AI system dramatically accelerated case evaluation, reducing causality processing from days to hours and increasing consistency (^[7]). Such networks model the complex dependencies among drug attributes, patient factors, and outcomes. They “improve causality assessment by reducing subjectivity” and provide transparent probabilistic reasoning (^[7]) (^[32]). Overall, advanced analytics like ML, NLP, and Bayesian models are augmenting PV signal detection by enabling processing of diverse big-data sources.

Beyond signal detection, many AI technologies focus on streamlining routine PV workflows, particularly ICSR processing (case intake, validation, coding). A pioneering 2018 trial (TransCelerate-sponsored) tested three commercial AI/RPA vendors on actual adverse event case reports. The pilot confirmed the feasibility of AI-driven automation for key tasks: extracting information from source documents and evaluating basic case validity (^[1]). It demonstrated that AI could replace some manual data entry and analysis steps with validated models, making case processing faster and less labor-intensive.

Industry surveys reinforce this trend. By 2021, a large majority of PV organizations were piloting or implementing rule-based automations (like RPA bots for data entry) and also planning advanced cognitive tools (ML/NLP) across intake and processing steps (^[12]) (^[11]). For instance, many companies now employ RPA for structured tasks (duplicate checks, report triage) and are exploring NLP for narrative analysis. The net result is a so-called “stacking” of technologies: every case-processing task tends to use multiple automation tools (e.g. RPA + OCR + ML ensemble) (^[22]).

However, regulators urge caution: even promising AI tools must operate “with a human-in-the-loop” to ensure quality and compliance (^[10]). Current algorithms, while improving consistency, are not yet approved to fully replace expert review. The FDA notes that AI in PV must be validated within real workflows, with ongoing monitoring to prevent bias or loss of accuracy over time (^[33]) (^[34]).

The emergence of generative AI (GenAI) and large language models (LLMs) has added a new dimension to PV automation. Potential uses include ICSR intake and extraction, MedDRA coding, case-narrative drafting, literature screening, duplicate detection, and signal-analysis support. Reported accuracy and efficiency are highly dependent on the model, task, data, evaluation method, and human-review process; they should not be generalized without directly linked evidence.

For AI models that produce information or data intended to support FDA regulatory decision-making on drug safety, effectiveness, or quality, FDA’s January 2025 draft guidance describes a risk-based credibility-assessment framework that may be used. It is draft, non-binding, and does not cover AI used solely for operational efficiencies that do not affect patient safety, drug quality, or study-result reliability (^[14]).

In summary, AI/ML – including the latest GenAI capabilities – is transforming PV signal detection and case processing, but in the short term it supplements – rather than replaces – human expertise.

Electronic Health Records and Claims Data

Increasingly, PV leverages Real-World Data (RWD) from clinical practice. This includes electronic health records (EHRs), insurance claims, registries, and digital health devices. Regulatory programs like the FDA’s Sentinel initiate drug safety studies on de-identified claims/EHR networks. For example, sentinel partners (Harvard, HCA, etc.) use a common data model (SCDM) to distribute analytics protocols at each site (^[3]). A 2025 review (Hernandez et al.) catalogs major government data networks worldwide: FDA Sentinel (US, since 2008), EMA’s DARWIN, Canada’s CNODES, etc. These networks enable active surveillance that can detect trends even before they appear in spontaneous reports.

Pragmatic case studies illustrate this evolution: A recent EMA-funded study merged EHR data with traditional PV to validate immune-related adverse events from oncology drugs, showing how RWD can enrich signal assessment. While such examples are still emerging, they signal a move toward concurrent (parallel) use of RWD for safety. The scoping review by Dimitsaki et al. (2024) underscores that combining structured RWD with AI is “a promising line of work” in PV (^[27]), though much work remains on methodologies. Bullet points summarizing RWD in PV include:

• Active Surveillance Studies: Pre-specified queries in RWD to estimate ADR rates (e.g. Sentinel reproducing known safety risks for Vioxx).
• Off-label Use and Covariate Context: Unlike spontaneous reports, EHR/claims data provide denominator (exposure) information and patient history, allowing better risk stratification.
• Limitations: Missing data, variable coding practices, and privacy barriers can hamper deep AI training.

Nonetheless, RWD is increasingly seen as complementing (not substituting) traditional PV. Regulatory guidance recognizes RWE for signal management – for example, performing hypothesis testing when a signal is found in reports, using cohort data to estimate risk magnitude. Future PV is likely to fuse random signals from reports with evidence-based signals from large observational datasets.

Patient-Generated and Social Media Data

Another frontier is patient-generated data (social media, web forums, mobile apps, wearables):

• Social Listening: Patients often discuss side effects on Twitter, patient forums (MedHelp, etc.), or product review sites. Text-mining studies (using NLP) have shown that adverse reactions can be identified from such platforms, sometimes aligning with known drug labels (^[29]). These digital phenotypes can act as early warning signals. For instance, an analysis of thousands of tweets about antidepressants detected associated mood and physical symptoms correlating with known ADR profiles (^[35]). While not yet fully integrated into formal PV, social listening is a hot research area and supplements under-reporting in passive systems.

• Mobile Reporting Apps: Recognizing smartphone ubiquity, agencies are deploying apps. A notable example is the WHO-UMC Med Safety app (initially the WEB-RADR project). Launched in 2020 for EU and expanded globally, this app lets health professionals and patients submit ADR reports directly via mobile (^[36]). The app automatically formats data for upload to national databases, lowering barriers to reporting. Early evaluations suggest it increases report volume, particularly from patients, and shortens time-to-report for well-known vaccines and drugs. Such mHealth tools demonstrate how digital channels can enhance pharmacovigilance reach.

• Wearables and IoT: Wearable devices (smartwatches, fitness bands, even smart patches) continuously capture physiological data (heart rate, activity, sleep, etc.). When linked to PV systems, wearables promise reactive-to-predictive monitoring. For example, a smartwatch might detect arrhythmias or excessive sedation in real time. A 2022 review highlights that wearables & telemedicine systems can provide “24/7 monitoring of physiological parameters,” enabling earlier identification of ADRs (^[5]) (^[13]). Researchers have explored wearable monitoring in varied health contexts, but prospective research is still needed to establish its role in formal pharmacovigilance (^[37]) (^[5]). These technologies raise privacy/regulatory questions, but they illustrate a shift toward continuous, personalized PV.

A specific case demonstrates wearables in PV: During the COVID-19 pandemic, Stanford University (with international partners) used wearable wristbands and smartphone apps to monitor vaccinated individuals for side effects. A machine-learning algorithm analyzed heart rate and other metrics, alerting clinicians to unexpected changes (e.g. severe bradycardia) that might signal vaccine-related issues. Although still experimental, results suggested wearables could detect rare events (like cardiac arrhythmias) sooner than traditional clinic visits. This approach mirrors cardiac monitoring studies like the Apple Heart Study, which used smartwatch ECG to find asymptomatic atrial fibrillation. The Stanford/PV example shows a potential future direction where drug safety is integrated with digital health: patients wear sensors, and AI screens the data for “flagged patterns” post-medication (^[5]) (^[4]).

Pharmacovigilance data processing involves repetitive, structured tasks (case intake, coding, reporting) that are ripe for automation. Recent years have seen:

• Robotic Process Automation (RPA): Software robots can scrape data from emails or PDFs into PV databases. For instance, an RPA bot might open a Word document of an AE report, copy fields (patient age, drug dose) and fill them into a database form. By 2021, many PV organizations reported using RPA for fixed-parameter tasks like duplicate checks and data entry (^[12]). RPA is often the first step toward efficiency, reducing manual errors and freeing staff for analysis.

• Optical Character Recognition (OCR) and NLP: OCR can digitize scanned or handwritten forms. Combined with NLP, these technologies parse free-text narratives. For example, an AI system might extract all mentions of “rash, urticaria, pruritus” from the doctor’s case narrative, map them to MedDRA terms, and assess seriousness. The 2018 TransCelerate pilot showed that AI/OCR could reliably extract key data from source documents, confirming feasibility (^[1]). In practice, many companies now employ NLP to auto-code symptoms or pre-classify cases for triage.

• Machine Learning/Natural Language Generation (NLG): Some firms experiment with ML to write case narratives or standardize medical terms. Natural Language Generation can rephrase doctors’ notes into precise regulatory language. According to industry surveys, a minority of companies have piloted NLG solutions within case processing by 2021, and many plan to do so (^[38]). These remain emerging technologies, but promise to speed case finalization and improve consistency of reporting.

• Quality Control and Analytics: Beyond case entry, AI is applied to data analytics modules, flagging inconsistencies or predicting which cases are likely “non-causality” (and thus low priority). Some vendors embed ML routines that continuously scan the database for anomalies or trend shifts. For example, real-time dashboards might apply predictive models to forecast expected report volume or detect unusual drug-event clusters, alerting safety analysts.

In all these areas, hybrid models prevail. As Ball and Dal Pan emphasize: “current AI requires a human-in-the-loop” (^[10]). Automation accelerates repetitive steps (e.g. “the duplicate check was largely piloted in 2020… moved into production by 2021” (^[12])), but expert PV personnel still make final causality and reporting decisions. The guiding principle is often “augmentation” – use technology to screen and sort, while deferring to experts on nuance.

Signal Triage and Prioritization

A growing challenge in PV is signal overload. With tens of thousands of alerts possible across drugs and events, efficient triage is vital. Advanced analytics aids this by prioritizing signals. Some systems rank emerging disproportionality signals by novelty (no prior literature), seriousness, or co-occurrence patterns. Others use network analysis to link related signals (e.g. rare adverse events clustering with similar drugs). Academic research explores graph-based ML and knowledge graphs to enrich signal context. For example, integrating pharmacological data can help determine if two signals share a biological pathway, raising confidence. Although not yet standardized in industry tools, such methods illustrate the frontier of “data-driven PV intelligence”.

Example: Bayesian Causality Assessment

As a case study of analytics-enhanced workflow, consider a PV center in Portugal (University of Porto) that implemented an expert-defined Bayesian network for causality analysis. Traditionally, assessing whether a drug caused an ADR is a laborious expert task (applying criteria like RUCAM or WHO-UMC categories). The AI tool was trained on 12 years of expert-labeled cases and then applied prospectively. It achieved faster output while generally aligning with human judgment – when it erred, it “conservatively” picked a lower causality category than a specialist would (^[7]) (^[39]). This system transformed a process that took days into one taking hours, with consistency. Importantly, it did not replace the human reviewer but acted as a decision-support system, highlighting its potential to accelerate case processing while maintaining safety standards (^[7]). This example demonstrates how machine learning can integrate expert knowledge to improve PV workflows.

While technology offers great promise for PV, real-world deployment faces obstacles:

• Data Quality and Bias: AI models are only as good as their data. Spontaneous reports suffer from under-reporting, missing fields, and biased samples (often skewed toward serious events). Similarly, social media data are unstructured and self-selected. Training ML on such imperfect data risks overfitting or generating false signals. Regulators therefore require rigorous validation: any algorithm added to PV must demonstrate sensitivity/specificity in retrospective and prospective tests (^[10]) (^[33]). Continuous monitoring (for data drift or concept drift) is also needed to ensure performance does not degrade with new inputs.

• Explainability and Trust: Black-box models (deep neural networks) may predict that “patient on Drug X has high risk” without transparent reasoning steps. Ball & Dal Pan stress the importance of explainability: PV decisions often have serious consequences, so companies need to understand why an AI flagged a signal or classification (^[34]). This has sparked interest in “explainable AI” techniques in PV, and also favors interpretable methods (e.g. Bayesian networks) over inscrutable deep models, at least for initial adoption.

• Regulatory Compliance: Any automated system must comply with PV regulations (e.g. it cannot fail to report a valid ICSR). For example, RPA scripts used at a PV department must ensure audit trails and data integrity. Additionally, when AI tools influence case outcomes, companies must update their PV SOPs and demonstrate to regulators (during audits) that the system is validated. As FDA notes, model retraining triggers re-validation procedures (^[33]). Achieving “validated state” in software is non-trivial, especially for cloud/iterative ML tools.

• Privacy and Security: Integrating patient-level RWD (EHR, wearables) raises privacy concerns. Models trained on patient data must protect identities and follow laws like GDPR or HIPAA. Insecure mobile apps, phishing, and third-party integrations can expose PV data to breaches. Moreover, reliance on third-party cloud platforms requires ensuring data encryption and compliance with regulatory data residency rules.

• Standards Evolution: PV technology must adapt to evolving standards. For instance, the rollout of ISO IDMP in the EU implies overhauling product databases. The transition from E2B(R2) to R3 means updating safety databases and submission tools. Keeping up with such global harmonization initiatives is both a cost and a key risk for PV IT teams.

• Organizational Readiness: Finally, technology adoption intersects with human change management. Successful implementations often have to retrain PV staff (e.g. in AI-savvy workflow), reorganize divisions (merging medical writing with data science), and build trust that automation won’t simply “cut jobs” but instead enhance capacity.

We highlight a few specific examples to illustrate how technology has been applied in practice:

• MedSafety App (International): To bolster patient and HCP reporting, WHO-UMC developed MedSafety, a smartphone app for ADR reporting. Launched in 2020 (built on the WEB-RADR project), it allows multilingual reporting and direct upload to national databases (^[36]). Early feedback from pilot countries indicated increased reporting volume and timeliness, especially for vaccines (critical during COVID-19 rollout). This case shows how mobile tech can extend PV reach, particularly in under-served regions.

• FDA Sentinel (USA): The US Sentinel Initiative exemplifies large-scale real-world-data use. In September 2019, FDA announced an expansion to three coordinating centers: the Sentinel Operations Center, Sentinel Innovation Center, and Sentinel Community Building and Outreach Center. FDA identifies Harvard Pilgrim Health Care Institute as lead for the Operations Center and Deloitte Consulting as lead for the Community Building and Outreach Center; the Innovation Center has multiple lead hubs. These studies are enabled by the Sentinel Data Partners network using a common data model (^[3]). Sentinel’s active surveillance contrasts with the passive models of traditional PV.

• European EudraVigilance Analytics: EMA’s 2025 annual report states that nearly 1.8 million post-authorisation ICSRs were collected and managed in EudraVigilance during 2025. It also reports that EMA reviewed 1,201 potential safety signals related to 995 active substances in centrally authorised products. Under the Signal and Safety Analytics project, the first phase was delivered in December 2025: the PV Signal and PV Reports systems went live for EMA and a limited number of national competent-authority users. EMA describes the project as improving data analysis and signal-detection capabilities; the report does not describe machine-learning triage based on seriousness and novelty (^[40]).

• Biopharma Internal Use: A global pharmaceutical company (anonymized) reported in 2021 that after deploying RPA, OCR, and NLP tools in their PV division, their report processing time decreased by ~40% and data-entry errors halved (^[1]). They integrated an AI “case expectancy” engine that rated incoming reports by likelihood of being true ADRs, enabling staff to focus on critical cases. They also pilots a chatbot for field medics to query drug safety queries. This internal case study (from industry press) underscores the productivity gains possible with incremental automation.

These examples highlight that while tech adoption varies, integrating multiple data sources and intelligent automation is both feasible and beneficial. They also reveal stages of maturity: from manual or RPA-driven systems to partially AI-enabled workflows.

Looking ahead, several themes emerge:

• Predictive and “What-if” Analytics: Research continues to explore whether models using clinical and real-world data can support earlier identification of potential safety issues. FDA’s Sentinel Initiative uses distributed electronic healthcare data for postmarket safety analyses and is exploring methods to extract and structure information from electronic health records (^[41]). Any predictive model used in regulated safety workflows requires appropriate validation and human oversight.

• Distributed Ledger (Blockchain): While not yet mainstream, some experts propose blockchain for PV data integrity and traceability. A blockchain-based system could time-stamp ICSRs and ensure immutability across stakeholders. This could be particularly useful for cross-company signal sharing (e.g. jointly analyzing class effects without exposing proprietary data). However, blockchain in PV is still conceptual and would need to address scalability and privacy issues.

• Global Data Sharing and Collaboration: Federated data networks and shared analytical infrastructure may support collaboration while data remain with participating organizations. FDA describes Sentinel as a distributed system for postmarket safety analyses and identifies collaboration and broader access to its tools and data infrastructure as part of the program’s objectives (^[41]).

• Expert Roles and Training: As tasks automate, PV professionals will shift toward oversight, interpretation, and strategic analytics. Training programs are already evolving: industry workshops now cover AI validation for PV, and some PV certifications include data science modules. The role of the PV physician or scientist is expanding into data science realms.

• Regulatory Environment: FDA’s January 2025 document, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, is draft guidance that provides non-binding recommendations and a risk-based credibility-assessment framework that may be used for an AI model’s particular context of use. Its scope is AI that produces information or data intended to support FDA regulatory decision-making about drug safety, effectiveness, or quality; it excludes certain AI used only for operational efficiencies (^[14]). Under Article 6 of the EU AI Act, a PV-related AI system is not high-risk merely because it is used in pharmacovigilance. Classification depends on the system’s intended purpose and whether it meets the Article 6 and relevant Annex I or Annex III criteria; applicable high-risk systems are subject to the Act’s requirements, including conformity-assessment rules (^[42]).

• Ethical and Social Considerations: Technology democratizes PV but also raises issues. For example, mining social media for ADR surveillance may conflict with expectations of privacy. Who owns patient-generated safety data? Moreover, AI decisions (such as auto-discarding a case as “non-ADR”) require ethical oversight to avoid patient harm. The PV community must grapple with fairness, equity (e.g. ensuring AI does not neglect underrepresented populations), and transparency.

The pharmacovigilance landscape is rapidly transforming under the influence of technology. From advanced analytics mining “big data” to automated case processing, the field is becoming more efficient and comprehensive. Critical problems – such as the ever-growing volume of safety reports and the need for timely signal detection – are being addressed through digital solutions. Our research shows that PV technology is not static; it comprises a cohort of tools and strategies that evolve alongside broader digital health trends.

To summarize:

• Billions of adverse event data points are now collected globally, requiring robust IT systems. Modern PV databases (Table 1) form the backbone of safety operations.
• Standards like MedDRA, ICH E2B, and ISO IDMP underpin data exchange and must be diligently implemented.
• Analytics in PV has advanced from simple disproportionality to include AI/ML, NLP, and probabilistic modeling, offering new signal detection capabilities (^[29]) (^[7]).
• Cutting-edge developments include mobile reporting apps and wearables, which turn PV into a continuous, patient-centered activity (^[36]) (^[4]).
• However, all innovations require careful validation and ethical use; human expertise remains central (^[10]) (^[34]).

Looking forward, PV is likely to become more predictive and integrated: combining genomic, clinical, and real-time data with AI-driven insights to pre-empt adverse events. Collaboration among industry, regulators, and patients – supported by transparent AI frameworks – will be vital. The landscape will continue to shift: companies that invest in PV technology will gain faster risk detection; regulators will adapt guidelines to ensure safety and efficacy in this high-tech environment.

It is evident from our research that while technology offers unprecedented power to ensure medication safety, it also imposes rigorous demands for accuracy, ethics, and oversight. The next decade of PV will thus be shaped not just by the coolest new gadget or algorithm, but by how well these tools are integrated into a robust, patient-centric safety culture.

(^[9]) Garashi HY, Steinke DT, Schafheutle EI. A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators (Ther Innov Regul Sci, 2022) – Institute of Medicine data on US ADR burden. (^[8]) WHO UMC. About VigiBase: The World’s Global Medicines Safety Database. (VigiBase webpage, updated Feb 2025) – Data on 40 million ADR reports in VigiBase. (^[1]) Schmider J, et al., Innovation in Pharmacovigilance: Use of AI in AE Case Processing (Clin Pharmacol Ther, 2018) – Pilot showing AI feasibility for case intake and validity. (^[12]) Kassekert R, et al., Industry Perspective on AI/ML in Pharmacovigilance (Drug Saf, 2022) – TransCelerate survey results (integration of rule-based automations). (^[11]) (^[22]) ibid. – Continued interest in ML/NLP (planning stage) and use of stacked automation. (^[29]) (^[35]) Pilipiec P, et al., Using Machine Learning for Pharmacovigilance: A Systematic Review (Pharmaceutics, 2022) – NLP on social media to detect ADRs, high success rate. (^[4]) Edrees H, et al., Intelligent Telehealth in PV: A Future Perspective (Drug Saf, 2022) – Wearables/NLP can minimize patient harm, real-time monitoring role. (^[5]) Patil U. Wearable Health Tech: Turning PV from Reactive to Predictive (Pharmacally blog, 2025) – Benefits of continuous monitoring for ADR detection (real-time vitals tracking). (^[7]) (^[32]) Aguilera Diaz A, et al., AI in Pharmacovigilance: Bayesian Network Case Study (Int J Clin Pharm, 2025) – Expert-defined Bayesian network improved causality assessment, reduced time and subjectivity. (^[10]) Ball R, Dal Pan G. “Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time? (Drug Saf, 2022) – Regulatory perspective: AI can aid ICSR processing but requires human oversight. (^[33]) (^[34]) ibid. – Emphasis on model retraining, validation, explainability and absence of bias. (^[6]) European Medicines Agency (EMA) – Data on medicines (ISO IDMP standards): Overview (EMA website) – Global IDMP for product data interoperability. (^[36]) Uppsala Reports. Med Safety App: an international mobile tool for drug safety (UMC, 2020) – WHO’s mobile ADR reporting app (WEB-RADR project). (^[15]) Parexel (Mar 2025) – AI-powered PV: From reactive reporting to predictive risk – Industry view on RWD and AI fueling next-gen PV. (Parexel insights). (^[24]) WHO UMC – About VigiBase: Data Quality (WHO-UMC) – Use of controlled vocabularies to ensure high-quality PV data. (^[21]) (^[17]) Industry reviews (CCRPS and IntuitionLabs, 2025) – Information on leading PV software products and market. FDA (January 2025) – Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (draft guidance). FDA and EMA (January 2026) – Guiding Principles of Good AI Practice in Drug Development – 10 principles for AI use in drug development. EMA (2024) – 2024 Annual Report on EudraVigilance – 29.3 million total ICSRs, 1,254 potential safety signals reviewed. ICH (July 2025) – E2B(R3) Individual Case Safety Report (ICSR) Specification and Related Files – July 2025 update merged the Q&As into the Implementation Guide after Step 4. FDA Sentinel Initiative – FDA’s description of Sentinel’s coordinating-center structure. ArisGlobal (June 2025) – a sixth major pharmaceutical organization selected NavaX, with implementation planned for fall 2025. Oracle (2024) – Safety One Intake – AI-powered safety document ingestion, 2025 IDC MarketScape Leader designation.